The presence of sleep disordered breathing (SDB) is known to impact long-term cardiovascular morbidity in adults; however, the long-term effects in children are poorly understood. We aimed to systematically review and synthesize studies published to date on the long-term effects of SDB in children. Study Design: Meta-analysis and systematic review using PubMed, CINAHL, Embase, and Scopus (all indexed years). Methods: We searched for English-language articles containing original human data from prospective studies, with ≥7 participants, in children ≤18 years of age. Data regarding study design, demographics, clinical characteristics, outcomes, level of evidence, and risk of bias were obtained. Articles were independently reviewed by three investigators. Retrospective and cross-sectional studies were excluded. Results: Of 1701 identified abstracts, 25 articles (combined n = 1418) were ultimately included. All studies reported longitudinal outcomes following treatment of SDB, 21 studies exclusively reporting outcomes after adenotonsillectomy. Therefore, studies were combined to objectively assess the effect of SDB treatment on cardiovascular outcomes. Although all cardiovascular parameters were within the normal range at baseline, at follow-up there was a significant decrease in mean pulmonary artery pressure, right ventricular end diastolic diameter, heart rate, mitral Em/Am ratio, and C-reactive protein. There was no significant change in interventricular septum thickness, left ventricular parameters (shortening fraction, systolic and end diastolic diameters, ejection fraction, posterior wall thickness, isovolumetric relaxation time), left atrial diameter, and aortic and pulmonary valve peak velocities. Conclusions: Studies assessing the long-term cardiovascular effects of SDB in children are limited. The available literature indicates effects on autonomic function, right, and left heart function following treatment for SDB. However, well-designed, large-scale, prospective cohort studies (using standardized outcomes) are needed to better understand the relationship of cardiovascular morbidity in the context of pediatric SDB.
INTRODUCTION
The estimated prevalence of pediatric obstructive sleep apnea (OSA) is 1% to 5% with peak prevalence occurring between 2 and 8 years of age. This disease can result in significant morbidity to multiple organ systems. 1 The effect of OSA on the cardiovascular system has been well characterized in adult longitudinal cohort studies such as the Sleep Heart Health Study 2 ; however, pediatric studies are limited. 3 In addition, many children are treated for OSA based upon the presence of sleep disordered breathing (SDB) symptoms, without formal diagnosis of OSA. While single-center, cross-sectional studies assessing the effect of SDB presence and treatment on cardiovascular outcomes exist, longitudinal studies are few. Currently available systematic reviews are limited by the number of outcomes reported or qualitative nature. [4] [5] [6] [7] There is one meta-analysis of cohort studies on echocardiographic findings in pediatric OSA. 5 One limitation of this study is the sole inclusion of echocardiographic markers of cardiovascular disease, report of only four outcomes, and meta-analysis comparing OSA to controls without comparisons of outcomes before and after treatment for OSA. Therefore, our aim was to systematically review the literature regarding the long-term effects of SDB on cardiovascular outcomes in children and perform a meta-analysis of previously reported cardiovascular outcomes in the context of pediatric SDB.
MATERIALS AND METHODS

Study Selection
We followed the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) recommendations to perform this review ( Figure 1 ). Studies were included if they evaluated changes in cardiovascular parameters at 2 or more time points, were prospective, contained an abstract, involved only patients ≤18 years, were published in English and included ≥7 subjects. We excluded review articles, animal studies, and articles without original data. For the meta-analysis section, we excluded studies with longitudinal outcomes measured <1 month or >1 year from the reported baseline. Studies documenting OSA or SDB were combined, given the limited number of studies assessing cardiovascular outcomes using echocardiography in children with polysomnogram confirmed OSA. Practice guidelines and review articles were reviewed to identify additional studies. This study was exempt from evaluation by the institutional review board.
Types of Outcome Measures
Our primary outcomes of interest were cardiovascular abnormalities measured by echocardiography or another validated test (electrocardiography, photoplethysmography, ultrasound)
Statement of Significance
Studies prospectively assessing the long-term effects of OSA including the effect of treatment (either medical or surgical) on cardiovascular parameters in children with obstructive sleep apnea are limited. Future prospective studies, utilizing polysomnography for diagnosis, are needed to better understand the effects of OSA on cardiovascular outcomes in children.
and serum biomarkers of endothelial function. Outcomes were organized in the following categories according to the function that was measured: autonomic dysfunction, endothelial function, right heart morphology and function, and left heart morphology and function.
Data Sources and Study Selection
With the help of a medical librarian, we searched PubMed, CINAHL, Embase, and Scopus on September 23, 2015, to identify relevant studies using combined key terms and exploded Medical Subject Headings (MeSH; Table 1 ).
Three investigators (R.S.A., S.L.I., and Z.E.) independently reviewed all identified titles, abstracts, and full-text articles. Disagreements were discussed and resolved by consensus. Outcomes were included in the meta-analysis if there were 2 or more studies, and the heterogeneity statistic (χ 2 ) had a p value > .05. For studies with incomplete results information, we contacted authors via e-mail for additional data (2 of 12 responded). 
Data Extraction and Quality Assessment
For each study, we recorded the author, year of publication, study design, inclusion criteria, intervention, length of follow-up, and outcome. The level of evidence was determined according to the Center for Evidence-Based Medicine guidelines. 8 Triplicate evaluation of the Newcastle-Ottawa Scale for assessment of quality of nonrandomized studies in meta-analysis 9 was used (S -Table 2a ). The Cochrane Collaboration tool for risk of bias 10 was used to evaluate randomized controlled trials (S -Table 2b ).
Statistical Analysis and Effect Size Calculation
We used the DerSimonian and Laird 11 random effects model to calculate the summary post-and pre-intervention differences for SDB subjects who underwent adenotonsillectomy (T&A). Outcomes reported by OSA severity were combined; weighted mean and pooled standardization were used for meta-analyses. We calculated the mean differences (MD) and the 95% confidence intervals (CIs) and presented the results in forest plots.
Test for overall effects were based on z-statistics and associated p values.
A heterogeneity test was performed by using the χ 2 and I 2 statistics. 12 We classified heterogeneity based on the following I 2 threshold values: 0-40%: no significant heterogeneity; 30-60%: moderate heterogeneity; 50-90%: substantial heterogeneity; and 75-100%: considerable heterogeneity. For the χ 2 statistic, a p value of < .05 was considered statistically significant heterogeneity. If there was a substantial heterogeneity, the sources of heterogeneity were explored by removing studies with low methodological quality. For studies with significant heterogeneity, meta-analysis was not performed. All statistical analyses were conducted using the "metafor" package in R version 3.2.3 (R Core Team, Vienna, Austria).
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RESULTS
Of the 1701 abstracts initially identified, 25 were included in the final review (n = 1418). The mean Newcastle Ottawa score was OR "Hypotension" OR "pulse" OR "Coronary Artery Disease" OR "Cardiac Arrhythmias " OR "Stroke" OR "Hemodynamics" OR "Electrocardiography" OR "Atrial Function" OR "Heart Failure" OR "Nitric Oxide" OR "Pulmonary Hypertension " OR "Baroreflex" OR "Pressoreceptors" OR baroreceptor OR "Chemoreceptor Cells" OR "Natriuretic Peptides" OR "Cardiac Output" OR "Heart Rate" OR "Echocardiography" OR "Ventricular Dysfunction" OR "Ventricular Remodeling" OR "Hypertension" OR "Endothelium" OR "Atherosclerosis" OR "Autonomic Nervous System Diseases" OR "Autonomic Nervous System" OR "Blood Pressure" OR "Cardiovascular System" ) ) ) AND ( "long term" OR "long-term" OR longitudinal OR prospective OR "follow up" OR "follow-up" OR "clinical trial" OR "randomized controlled trial" ) AND ( LIMIT-TO ( LANGUAGE , "English" ) ) 8/9. All studies included adenotonsillectomy as an intervention, 21 exclusively. Of note, in four studies, a small proportion of each cohort was treated with medical management (CPAP, nasal steroids). [15] [16] [17] Details of the included studies are reported in Table 2 . Key outcome measures that were consistent between studies are depicted in S-Tables 3a-d. A description of the cardiovascular outcomes reported in this review are provided in the Online Supplement. The mean ages ranged from 5 to 13 years for the SDB and control groups (those who did not undergo intervention). Sixteen studies used polysomnography to diagnose OSA, whereas nine diagnosed SDB clinically. The effect of SDB treatment on cardiovascular outcomes are meta-analyzed and reported susequently. We also performed a meta-analysis of studies comparing SDB cases versus nondiseased controls. The results are depicted in the Online Supplement (S- Figure 1 -8) .
Autonomic Dysfunction
Two studies assessed blood pressure in SDB children. 15, 18 A significant decrease in asleep DBP at 6 months 18 and asleep SBP and DBP at 4 years after T&A 15 were reported. Changes in ambulatory BP parameters were not observed. Meta-analysis was not performed.
Three studies assessed awake heart rate (HR). 15, 19, 20 For the two studies included in the meta-analysis, there was a significant decrease in HR at follow-up ( Figure 2 ; [MD −2.97;CI 95% −5.18 to −0.77]). There was also a significant increase in RR interval (n = 3 studies 18, 21, 22 ; Figure 3 ; [MD 0.03;CI 95% 0.00, 0.06]). Additionally, there were significant improvements in overnight baroreflex sensitivity, 18 BP variability, 15, 18 asleep HR and HR variability, 16 and systolic and diastolic BP indices (in those with resolved SDB) 23 after treatment.
Endothelial Function
One study assessed endothelium-dependent, flow-mediated dilation (FMD) using ultrasound of the brachial artery; it reported a significant increase in FMD after AT in the surgical intervention group and no significant change after treatment with nasal steroids in the nonsurgical group. 24 One study used a modified hyperemic test after cuff-induced occlusion of the brachial artery, reporting a significant improvement in response after treatment with AT 25 . After AT, there was a significant decrease in endothelin-1 26 , soluble CD40 ligand, 25 NT-proBNP 27 and morning brain natriuretic peptide level, 28 an increase in circulating adropin concentration (in OSA children with endothelial dysfunction) 29 and no significant change in cICAM-1 30 . Four studies assessed change in C-reactive protein. 27, [30] [31] [32] After removing sources of heterogeneity, 30 there was significant decrease in C-reactive protein at follow-up ( Figure 19 ; [MD −0.41;CI 95% −0.48 to −0.35]).
Right Heart Morphology and Function
Three studies assessed change in tricuspid E/A ratio (peak early filling to filling during atrial contraction). 19, [33] [34] [35] After removing sources of heterogeneity, 19, 33 there was no significant change in tricuspid E/A ratio at follow-up ( Figure 4 ; [MD −0.02;CI 95% −0.08 to 0.04]. Two studies reported a significant increase in tricuspid Em/Am ratio (early to late diastolic myocardial velocity). Meta-analysis was not performed (p = .0006). 33, 35 Six studies reported estimated mean pulmonary artery pressure (mPAP) using Mahan formula. 19, 33, [36] [37] [38] [39] After removing sources of heterogeneity, 33, 36, 38 there was a significant decrease in mPAP ( Figure 5 ; [MD −5.59;CI 95% −7.19 to −3.99]). Two studies reported estimated pulmonary artery systolic pressure 33, 35 ; although neither reported the proportion of children with pulmonary hypertension, both showed a significant improvement at follow-up. Meta-analysis was not performed.
Three studies assessed interventricular septum thickness (IVS). 35, 40 There was no significant change at follow-up ( Figure 6 ; [MD −0.19;CI 95% −0.69 to 0.31]). Four studies assessed right ventricular diastolic diameter (RVDd). 19, [40] [41] [42] After removing sources of heterogeneity, 41 there was a significant decrease in RVDd in the SDB group (Figure 7; [MD −0.12;CI 95% −0.20 to −0.03]. Two studies reported the right ventricular myocardial performance index (RVMPi) 33, 42 ; both showed a significant reduction (suggesting improvement) at follow-up. Due to heterogeneity between studies, meta-analysis was not performed. The two studies assessing pulmonary valve peak velocity showed no significant change at follow-up ( Figure 8 ; [MD 1.90; CI 95% −0.31 to 4.12]). In reviewing unique outcomes across studies, there were significant increases in RV ejection time, 42 time to peak velocity of pulmonary artery flow(TPV), 19 velocity-time integral of tricuspid flow(VTItv), 1 and velocity-time integral of pulmonary flow (VTIpa) 7 and a significant decrease in right ventricular isovolumetric relaxation time (IVRT) 15 and tricuspid regurgitation (TR). 43 There was no significant change in tricuspid full diastolic filling time, 34 tricuspid annular point systolic excursion, 44 RV Isovolumetric contraction time (IVCT), 41 and tricuspid E/E' (ratio of early tricuspid inflow to annular diastolic velocity).
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Left Heart Morphology and Function Three studies assessed LV diastolic function (mitral E/A ratio). 17, 34, 35 After removing sources of heterogeneity, 35 there was no significant change in mitral E/A ratio at follow-up ( 34, 35, 41, 42 with treatment. Two studies reported left ventricle myocardial performance index(LVMPi) 41, 42 ; both reported a significant decrease in LVMPi at follow-up. Meta-analysis was not performed.
Three studies assessing left atrial diameter (LA) showed no significant change ( Figure 14 ; [MD 0.03;CI 95% −0.06 to 0.12]). 34, 40, 42 Analysis of two studies showed no significant change in either LV ejection fraction ( Figure 15 ; [MD −0.26;CI 95% −3.02 to 2.50]) or aortic valve peak velocity ( Figure 16 ; [MD 1.70,CI 95% −1.66 to 5.06]). 34, 35 The two studies assessing left ventricle posterior wall thickness (LVpw) also showed no significant change (Figure 17 ; [MD −0.21,CI 95% −0.56 to 0.14]). 35, 40 Three studies reported left ventricular isovolumetric relaxation time (LV IVRT). 35, 40, 42 After removing the source of heterogeneity, 42 there was no significant change at follow-up (Figure 18 ; [MD 3.50,CI 95% −2.16 to 9.16]). One study showed a decrease in LV mass (indexed to BSA), 41 while another reported no significant change in LV mass(indexed to height). 35 One study reported a significant decrease in LV ET 42 . Changes in mitral E/E', 15 deceleration time, 40 LV peak filling velocity, 33 LA contraction velocity, 11 and LV IVCT 45 were not observed with treatment in individual studies.
DISCUSSION
In this systematic review and meta-analysis, we evaluated the longitudinal cardiovascular changes reported for children with SDB/OSA. All included studies reported outcomes before and after treatment (primarily with T&A). Differences in outcomes in SDB/OSA children compared to controls at baseline were also ascertained and depicted in the supplement. Overall, we found that a number of measures improved after treatment, but the mean values both before and after treatment were typically within the normal range. After treatment (most commonly with T&A), these children had significant decreases in mPAP, RVDd, awake HR, RVDd, and C-reactive protein and significant increases in RR interval and mitral Em/Am ratio. These outcome parameters are markers for pulmonary hypertension (mPAP), LV diastolic function (mitral E/A), RV dysfunction (RVDd), baroreflex function (RR interval and awake HR), and endothelial dysfunction (C-reactive protein). Although the synthesis of results is not definitively convincing for significant cardiovascular strain at baseline, the change following treatment may suggest that early signs of cardiovascular dysfunction may be present in these children. There is concern that childhood disruptions in the cardiovascular system may result in lifelong cardiovascular morbidity, although further work is necessary to better understand this relationship. 46 It is important that we review currently available evidence carefully, as subtle (albeit non-significant) effects on cardiovascular parameters may be additive over time.
There is sufficient evidence to suggest that severe OSA in adults significantly increases the risk of cardiovascular disease, stroke, and all-cause mortality. [47] [48] [49] Adults with SDB, regardless of severity, have a 2-3 time greater risk of developing hypertension at 4-year follow-up compared to controls. 50 While the cardiovascular morbidity of OSA in children has been summarized previously, 51, 52 meta-analyses are limited by low level of evidence, as the majority of published studies are cross-sectional or retrospective, [4] [5] [6] [7] and available reviews are primarily qualitative in nature. 53 
Autonomic Dysfunction
Obstructive events during sleep lead to increased sympathetic nervous system activation, which in turn may contribute to elevated BP. Pediatric cross-sectional studies show that primary snoring and SDB is associated with increased BP. 44, 45, [54] [55] [56] [57] Our results indicate that upon resolution of OSA, there was a significant decrease in nocturnal BP at 6-month 18 and 4-year follow-up 58 . Additionally, when evaluating the baseline characteristics of children included in this review, we found that when compared to controls, children with SDB had higher baseline nocturnal SBP and shorter RR interval (S- Figures 1-2) . Carotid sinus and aortic arch stretch receptors modulate the baroreflex which is a feedback loop that regulates BP. Children with OSA have altered baroreceptor sensitivity (BRS) which improves with resolution of OSA. 15, 18, 59 Although retrospective studies indicate HR variability is altered in children with SDB, 60, 61 prospective research is limited. 16 The decrease in heart rate, improvements in overnight baroreflex sensitivity, 18 BP variability 15, 18 and heart rate variability, 16 and systolic and diastolic blood pressure indices (in those with resolved SDB) 23 at follow-up suggests an improvement in sympathetic imbalance after treatment of SDB.
Endothelial Function
OSA has also been linked to impaired endothelial function-a risk factor for atherosclerosis-related vascular disease. 62, 63 Moreover, treating OSA with CPAP has been shown to improve endothelial function. 64 The majority of currently available pediatric evidence is cross-sectional in nature. [65] [66] [67] [68] [69] When assessing endothelium-dependent FMD of the brachial artery, the gold standard in assessing endothelial function, 70 OSA children have lower values compared to controls at baseline, with reversal of these changes after AT 24 . Measuring endothelial function with a modified hyperemic test after cuff-induced occlusion of the brachial artery yields similar results suggesting an improvement in endothelial function after OSA treatment. 25 Prospective studies reporting serum biomarkers reflective of endothelial function provide further support that associations in the context of OSA exist and improvement occurs after treatment. C-reactive protein (CRP) is a marker of inflammation and a potentially useful biomarker of cardiovascular morbidity. Studies reporting C-reactive protein as a marker of inflammation in the context of metabolic consequences of OSA were not within the scope of this review. A comprehensive review of biomarkers related to OSA has been previously reported 71 as well as a meta-analysis on the effects of T&A on C-reactive protein.
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Right Heart Morphology and Function
Although the baseline values for mPAP and estimated pulmonary artery systolic pressure in the majority of studies were within normal range (<25 mm Hg) and the magnitude of changes after T&A were small, our results suggest that improvement may be seen shortly following intervention. Reductions in RVDd after intervention may indicate a decrease in RV dilation and improvement in RV reserve-although the magnitude of improvement reported was marginal. When compared to controls at baseline, we found that IVS thickness was significantly higher in SDB children (suggesting a potential effect on RV pressure overload), but no significant improvement was seen at follow-up. Although tricuspid E/A ratio did not change significantly at follow-up, it is difficult to determine whether the significant improvement in Em/Am ratio (albeit from a normal baseline) across individual studies represents normative changes over time or is suggestive of improvement in diastolic dysfunction after T&A. However, changes in RV ejection time, RV MPi, VTItv, VTIpa, TPV, RV ET, and RV IVRT observed in individual studies all suggest improvement in right heart morphology and function at follow-up. When evaluating the baseline characteristics of children included in this review, we found that when compared to controls, children with SDB had higher baseline mPAP, RVDd and IVS thickness, and lower tricuspid E/A ratio (S- Figures 3-6 ).
Left Heart Dynamics and Function
Cross-sectional studies suggest that SDB is associated with elevated BP in children and linked to higher left ventricular mass and left ventricular diastolic dysfunction. 17, 22, 73 The E/A ratio is a measure of diastolic function. Although baseline values for mitral E/A ratios were normal (>1), there was a significant increase in Em/Am ratio with treatment without a significant change in E/A ratio. Since assessment of Em/Am using Tissue Doppler Imaging is a more sensitive marker of diastolic dysfunction compared to E/A ratio assessment using traditional echocardiography, these findings suggest that more sensitive tools may be needed to detect these subtle changes in children. Although cross-sectional data suggests LV hypertrophy in children with SDB, 74 the two studies reporting LV mass at follow-up reported conflicting results. Ugur et al. reported no significant change at follow-up, while Attia et al. reported a significant decrease in LVMi (indexed to BSA) at follow-up. Although cohorts from both studies were of similar age and nonobese, indexing left ventricular mass to height may be more sensitive in detecting LVH. LVMPi is a sensitive diagnostic and prognostic indicator of both systolic and diastolic dysfunction; both studies reporting it showed a decrease with treatment as well as significant elevations at baseline when compared to controls. Changes in other markers of left sided dysfunction such as LVDd, LV EF, LA, LVpw LV IVRT, LVSd and FS were not observed. Among the studies reported in this review, we found that when compared to controls, SDB children had higher baseline LVMPi and lower mitral E/A ratio (S -Figures 7-8) .
In summary, although the majority of cardiovascular parameters in children with SDB are within the normal range at baseline, treatment has significant impact on markers of cardiovascular strain such as mean pulmonary artery pressure, right ventricular end diastolic diameter, HR, and mitral Em/ Am ratio. Since cardiovascular effects are additive over time, these results suggest that earlier diagnosis of SDB (and subsequent treatment) may prevent long-term cardiac morbidity. We did not find any significant changes in interventricular septum thickness, left ventricular parameters (shortening fraction, systolic and end diastolic diameters, ejection fraction, posterior wall thickness, isovolumetric relaxation time), left atrial diameter, and aortic and pulmonary valve peak velocities. Given the paucity of available data, it is difficult to conclude what cardiovascular parameters are most sensitive and relevant for this patient population. Certainly, more robust studies involving larger sample sizes may be more revealing. For example, in order to design a randomized controlled trial with equal numbers assigned to the treated and control group, one will need 72, 356, and 12 subjects in each group (total of 144, 712, and 24 subjects) to detect a significant postintervention difference in mPAP, RVDd, and mitral Em/Am ratio, respectively, to achieve 80% power at significance level of 0.05. For a pre-post design in which subjects serve as their own control, samples of 38, 180, and 8 will achieve 80% power respectively for detecting significant pre-and post-treatment difference in mPAP, RVDd, and mitral Em/Am ratio at a significance level of 0.05.
LIMITATIONS
Our study had several limitations. The literature regarding longitudinal changes in cardiovascular parameters is limited, and there is significant heterogeneity in diagnostic modalities and outcomes reported. Standards regarding reporting of echocardiogram parameters exist although have not been consistently used for research in this context. Some notable examples of this are the inconsistent use of z-scores and the different methods of indexing left ventricular mass by body size across studies. This hinders quantitative comparisons across studies. Moreover, only sixteen studies reported diagnosis of OSA based on polysomnography (the gold standard), while clinical symptoms and questionnaires were used to identify SDB in the remainder. Of the 16 studies documenting OSA with polysomnography, only 3 reported echocardiogram findings (1 study only reporting one outcome). Outcomes assessed across studies were not sufficient enough to separately consider these studies for quantitative analysis. Also, details regarding the severity of OSA, as well as improvement in polysomnogram parameters after treatment, were not consistently reported. Additionally, several demographic parameters such as gender, ethnicity, and obesity may have contributed to heterogeneity of outcomes (and potential confounding of results) and were not able to be controlled for in our analysis. Obesity is a known major risk factor for cardiovascular disease, and it is key that this be factored for when performing research studies pertaining to cardiovascular risk of SDB. In pediatrics, the variability in terminology and metrics used to define obesity (body mass index [BMI] , BMI percentile, and BMI z-score) further complicates comparison across studies. Six studies did not report BMI data 34, 38, 39, [75] [76] [77] ; three reported absolute BMI values 35, 41, 78 ; two reported BMI percentiles 79, 80 ; six reported BMI z-scores 20, 28, 30, 43, 58, 81 ; two specifically reported excluding children with BMI > 29 41, 82 ; one reported excluding those with BMI z-score > 2.99 20 ; and one reported body surface area instead of BMI data. 83 Despite these limitations, our review provides a comprehensive synthesis and evaluation of the available literature regarding longitudinal changes in cardiovascular parameters in children with OSA, reporting the largest collection of cardiac outcomes meta-analyzed to date.
CONCLUSION
Although cross-sectional studies in children show that SDB is associated with significant cardiovascular comorbidities, well-designed and long-term prospective studies are limited. The currently available literature indicates that SDB impacts sympathetic activity, right, and left heart function. Moreover, the treatment of SDB may result in a reduction in cardiovascular strain. Well-designed, large-scale, prospective cohort studies (using standardized outcomes) are needed to better understand the relationship of cardiovascular morbidity and SDB.
Gaps
There is limited information regarding the long-term impact
of OSA on cardiovascular morbidity in children, and this literature is fraught with heterogeneity. 2. Studies prospectively assessing the effect of treatment (either medical or surgical) on cardiovascular parameters in children with obstructive sleep apnea are limited. 3. Information regarding appropriate outcome measures to assess cardiovascular morbidity associated with pediatric OSA is necessary. 4. Prospective studies, utilizing polysomnography for diagnosis, are needed to better understand the effects of complete vs. partial treatment of OSA on cardiovascular parameters in children.
